$4.9 Billion Bipolar Disorder Market Analysis By Drug Class, Mechanism of Action, Region And Segment Forecasts, 2014 - 2025 - ResearchAndMarkets.com

DUBLIN--()--The "Bipolar Disorder Market Analysis By Drug Class (Mood stabilizer, Anticonvulsant, Antipsychotic, Antidepressant, Antianxiety), By Mechanism of Action, By Region, And Segment Forecasts, 2014 - 2025" report has been added to ResearchAndMarkets.com's offering.

The global bipolar disorder market is anticipated to reach USD 4.9 billion by 2025, growing at a CAGR of 2.10%

Government support for generating awareness about the bipolar disorder and technological advancements that facilitate accurate detection of a patient's mood and mental state are a few of the factors driving the growth of this market.

The rising prevalence of bipolar disorders is likely to propel market growth in the forecast period. Government initiatives also drive the market growth. For instance, International Bipolar Foundation's Social Security Disability Insurance (SSDI) or Supplemental Security Income (SSI) are programs offered by the Social Security Administration (U.S.) for the benefit of the people affected by bipolar disorder.

Besides, technological advancements in smartphones, smartwatches, and wearable devices improve diagnosis rates by capturing physiological, behavioral, and environmental data effectively to detect the patient's mood and mental state. Online self-management tools also result in timely intervention, thereby improving diagnosis rates and treatment rates for the disorder. However, the patent expiry of blockbuster drugs in this market is likely to impact market dynamics in the forecast period.

Additionally, the drugs in the bipolar disorder market are bound to face intense competition from generic drugs, as treatment options for bipolar disorder. Other factors likely to restrain market growth in the forecast period include side effects associated with bipolar drugs, and misdiagnosis of bipolar disorder.

Key Topics Covered:

Chapter 1 Research Methodology

Chapter 2 Executive Summary

Chapter 3 Bipolar disorder Market Variables, Trends & Scope

Chapter 4 Bipolar disorder Drug Class Estimates & Trend Analysis

Chapter 5 Bipolar disorder Mechanism of Action Estimates & Trend Analysis

Chapter 6 Bipolar disorder Regional Estimates & Trend Analysis, by Drug Class, and Mechanism of Action.

Chapter 7 Competitive Landscape

  • GlaxoSmithKline
  • Pfizer Inc.
  • Janssen Pharmaceuticals
  • Eli Lily
  • Allergan Plc.
  • Norvartis
  • AbbVie Inc.
  • Otsuka Holdings Co. Ltd
  • AstraZeneca

For more information about this report visit https://www.researchandmarkets.com/research/k4srj7/4_9_billion?w=4

Contacts

ResearchAndMarkets.com
Laura Wood, Senior Manager
press@researchandmarkets.com
For E.S.T Office Hours Call 1-917-300-0470
For U.S./CAN Toll Free Call 1-800-526-8630
For GMT Office Hours Call +353-1-416-8900
Related Topics: Mental Health , Mental Disorders Drugs

Contacts

ResearchAndMarkets.com
Laura Wood, Senior Manager
press@researchandmarkets.com
For E.S.T Office Hours Call 1-917-300-0470
For U.S./CAN Toll Free Call 1-800-526-8630
For GMT Office Hours Call +353-1-416-8900
Related Topics: Mental Health , Mental Disorders Drugs